BIOA (Bioage Labs) Other Gross PPE : $0.87 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Other Gross PPE?

Bioage Labs's Other Gross PPE for the quarter that ended in Dec. 2024 was $0.87 Mil.

Bioage Labs's quarterly Other Gross PPE increased from Jun. 2024 ($0.75 Mil) to Sep. 2024 ($0.92 Mil) but then declined from Sep. 2024 ($0.92 Mil) to Dec. 2024 ($0.87 Mil).

Bioage Labs's annual Other Gross PPE increased from Dec. 2022 ($0.32 Mil) to Dec. 2023 ($0.56 Mil) and increased from Dec. 2023 ($0.56 Mil) to Dec. 2024 ($0.87 Mil).

Bioage Labs Other Gross PPE Historical Data

The historical data trend for Bioage Labs's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Other Gross PPE Chart

Bioage Labs Annual Data

Trend

Dec22

Dec23

Dec24

Other Gross PPE

0.32

0.56

0.87

Bioage Labs Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Gross PPE	Get a 7-Day Free Trial				0.56	0.78	0.75	0.92	0.87

Bioage Labs Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Bioage Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

1445A South 50th Street, Richmond, CA, USA, 94804

Website

https://www.bioagelabs.com

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.